A股異動 | 宋城演藝(300144.SZ)大漲逾9%破頂 市值達600億元
格隆匯3月2日丨宋城演藝(300144.SZ)連續走強,近一個月漲幅達35%。現大幅拉昇至9.69%,報23.04元創歷史新高價,市值高達600億元。公司此前預計2020年虧損16~19億,其中演藝主業盈利1.10億元符合預期,但花房減值導致公司2020年業績顯著承壓。國信證券指出,花房2020年雖然拖累較大,但利空出盡後,公司未來反而可輕裝上陣謀發展。另外,“千古情”基礎上,公司在三亞、麗江、西安等項目籌備“愛在”系列,計劃於2021 年推向市場,進一步豐富演藝王國形態和多層次市場策略。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.